2008 JASN IMPACT FACTOR 7.505	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Full Text Full Text (PDF) All Versions of this Article: ASN.2006050517v1 17/8/2100    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by de Zeeuw, D. Articles by Henning, R. H. Search for Related Content PubMed PubMed Citation Articles by de Zeeuw, D. Articles by Henning, R. H.

Microalbuminuria as an Early Marker for Cardiovascular Disease

Dick de Zeeuw^*, Hans-Henrik Parving and Robert H. Henning^*

^* Department of Clinical Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands; and Steno Diabetes Center, Gentofte, and Faculty of Health Science, Aarhus University, Denmark

Address correspondence to: Dr. Dick de Zeeuw, Department of Clinical Pharmacology, Ant Deusinglaan 1, 9713 AV Groningen, The Netherlands. Phone: +31-50-3632810; Fax: +31-50-3632812; E-mail: d.de.zeeuw{at}med.umcg.nl

Excretion of albumin in the urine is highly variable, ranging from nondetectable quantities to milligrams of albumin and even grams of albumin. Microalbuminuria is defined as low levels of urinary albumin excretion of 30 to 300 mg/d. Microalbuminuria is highly prevalent; in hypertensive and diabetic populations, its prevalence varies from 10 to 40%. It is interesting that microalbuminuria also is found frequently in seemingly healthy individuals (5 to 7%). The variable excretion of albumin in the urine is related to the risk for the individual to develop cardiovascular (CV) disease: Absence or very low levels of albuminuria is associated with low CV risk, whereas the CV risk increases markedly with increasing amount of albumin in the urine (even within the now considered normal range). The predictive power of urinary albumin levels for CV risk is independent of other CV risk factors and not only is present in individual with diabetes and/or hypertension but also in healthy individuals. Treatments that lower albuminuria are associated with CV protection, as demonstrated in randomized, controlled trials of patients with diabetes as well as in patients with hypertension. There is preliminary evidence that albuminuria lowering is CV protective in healthy individuals with an elevated albumin excretion rate. Differences between individuals in their level of albumin excretion are already observed at a very early age (just after birth). In fact, the interindividual variability seems to be relatively constant in the first 5 decades of life, indicating that microalbuminuria is not necessarily a consequence of vascular damage at later age. Higher levels of urinary albumin seem to reflect the ordinary interindividual variability in (renal and systemic) endothelial function. Experimental data show that between strains and even within strains, rats at young age show a remarkable difference in individual endothelial function, and this is strongly related to the susceptibility of that rat to organ damage. In conclusion, albuminuria seems to be a sensitive marker very early in life for the susceptibility of an individual to CV disease. It therefore may be an ideal target for early primary prevention using CV-protective therapy regimens.

This article has been cited by other articles:

				O. S. Deveci, G. Kabakci, E. Tulumen, S. Okutucu, H. Aksoy, E. B. Kaya, U. Canpolat, K. Aytemir, L. Tokgozoglu, and A. Oto The Relationship Between Microalbuminuria and the Presence and Extent of Coronary Atherosclerosis Angiology, February 1, 2010; 61(2): 184 - 191. [Abstract] [PDF]

				J. Escobedo, J. S. Rana, M. S. Lombardero, S. G. Albert, A. M. Davis, F. P. Kennedy, A. D. Mooradian, D. G. Robertson, V. S. Srinivas, S. S. P. Gebhart, et al. Association Between Albuminuria and Duration of Diabetes and Myocardial Dysfunction and Peripheral Arterial Disease Among Patients With Stable Coronary Artery Disease in the BARI 2D Study Mayo Clin. Proc., January 1, 2010; 85(1): 41 - 46. [Abstract] [Full Text] [PDF]

				I. S. Anand, K. Bishu, T. S. Rector, A. Ishani, M. A. Kuskowski, and J. N. Cohn Proteinuria, Chronic Kidney Disease, and the Effect of an Angiotensin Receptor Blocker in Addition to an Angiotensin-Converting Enzyme Inhibitor in Patients With Moderate to Severe Heart Failure Circulation, October 20, 2009; 120(16): 1577 - 1584. [Abstract] [Full Text] [PDF]

				P. D. Reaven, N. Emanuele, T. Moritz, R. Klein, M. Davis, K. Glander, W. Duckworth, C. Abraira, and for the Veterans Affairs Diabetes Trial (VADT) Proliferative Diabetic Retinopathy in Type 2 Diabetes Is Related to Coronary Artery Calcium in the Veterans Affairs Diabetes Trial (VADT) Diabetes Care, May 1, 2008; 31(5): 952 - 957. [Abstract] [Full Text] [PDF]

				M. R. Weir Microalbuminuria and Cardiovascular Disease Clin. J. Am. Soc. Nephrol., May 1, 2007; 2(3): 581 - 590. [Abstract] [Full Text] [PDF]

				A. Kottgen, S. D. Russell, L. R. Loehr, C. M. Crainiceanu, W. D. Rosamond, P. P. Chang, L. E. Chambless, and J. Coresh Reduced Kidney Function as a Risk Factor for Incident Heart Failure: The Atherosclerosis Risk in Communities (ARIC) Study J. Am. Soc. Nephrol., April 1, 2007; 18(4): 1307 - 1315. [Abstract] [Full Text] [PDF]

				Y. Kida and T. Sato Pioglitazone vs Glimepiride and Carotid Intima-Media Thickness JAMA, March 28, 2007; 297(12): 1316 - 1316. [Full Text] [PDF]

				M. Barton, J. J. Mullins, M. A. Bailey, and M. Kretzler Role of Endothelin Receptors for Renal Protection and Survival in Hypertension: Waiting for Clinical Trials Hypertension, November 1, 2006; 48(5): 834 - 837. [Full Text] [PDF]

Copyright © 2009 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673